Sanofi announced the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and ...
Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with E...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “D...
Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), announced its investment in Illexcor Ther...
UCB, a global biopharmaceutical company, announced that Epilepsia published findings from the final analysis of the long-term open-label extension (OLE) st...
GC Cell, under the leadership of CEO Sungyong Won, announced the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5...
Gilead Sciences, Inc. presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company...
Merck, known as MSD outside of the United States and Canada, announced the opening of a new, $1 billion, 225,000-square-foot facility dedicated to va...
CervoMed Inc. a clinical-stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), announced positive ...
To gain a competitive edge, the company partnered with DelveInsight to analyze competitor launch timelines, first-to-market companies, ...
Aragen, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced two senior level appointments. Dr. Manjunath Rama...
Bristol Myers Squibb announced positive data from the pivotal Phase 3 POETYK PsA-2 trial (IM011-055) evaluating the efficacy and safety of ...
Roche announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will ...
Johnson & Johnson announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-t...
© 2025 Biopharma Boardroom. All Rights Reserved.
